A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer

Cancer

Volumn 116, Issue 15, 2010, Pages 3595-3602

  Shamash, Jonathan ^a   Stebbing, Justin ^b   Sweeney, Chris ^c   Sonpavde, Guru ^d   Harland, Steve ^e   Dawkins, Guy ^f   Brock, Cathryn ^g   Abelman, Walter ^e   Wilson, Peter ^a   Sanitt, Adam ^b   Oliver, Tim ^a   Powles, Thomas ^a,h  

^a BARTS HEALTH NHS TRUST   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^f PRINCESS ROYAL HOSPITAL   (United Kingdom)

^g CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^h WHIPPS CROSS UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Dexamethasone; Diethylstilbestrol; Prognostic index; Prostate cancer; Second line hormone therapy

Indexed keywords

BICALUTAMIDE; DEXAMETHASONE; DIETHYLSTILBESTROL; DOCETAXEL; FLUTAMIDE; GONADORELIN DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CASTRATE RESISTANT PROSTATE CANCER; CASTRATION; HUMAN; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RATING SCALE; THROMBOEMBOLISM; VALIDATION STUDY;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; DIETHYLSTILBESTROL; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RETREATMENT;

EID: 77955365725     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25194     Document Type: Article

References (17)

1. Cancer Research UK. Cancerstats. Available at: www.info. cancerresearchuk.org/cancerstats/. Accessed August 2009.
2. Graham J, Baker M, Macbeth F, Titshall V. Diagnosis and treatment of prostate cancer: summary of NICE guidance. BMJ. 2008;336:610-612. (Pubitemid 351439520)
3. Hussain M, Tangen CM, Higano C, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol. 2006;24:3984-3990.
4. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
5. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148-1159.
6. Petrylak DP, Ankerst DP, Jiang CS, et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst. 2006;98:516-521.
7. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2007;25:3965-3970.
8. Sternberg CN, Whelan P, Hetherington J, et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology. 2005;68:2-9. (Pubitemid 40675002)
9. Nishimura K, Nonomura N, Yasunaga Y, et al. Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer. 2000;89:2570-2576.
10. Sartor AO, Tangen CM, Hussain MH, et al. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer. 2008;112:2393-2400.
11. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003;21:1232-1237.
12. Bower M, Gazzard B, Mandalia S, et al. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med. 2005;143:265-273.
13. Stebbing J, Sanitt A, Nelson M, Powles T, Gazzard B, Bower M. A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy. Lancet. 2006;367:1495-1502.
14. Stebbing J, Sanitt A, Teague A, et al. Prognostic significance of immune subset measurement in individuals with AIDS-associated Kaposi's sarcoma. J Clin Oncol. 2007;25:2230-2235. (Pubitemid 46954648)
15. Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res. 2007;13:6396-6403.
16. Kerr C. Satraplatin for hormone-refractory prostate cancer. Lancet Oncol. 2007;8:290.
17. US Food and Drug Administration. FDA briefing document: Oncologic Drugs Advisory Committee meeting NDA 21801 (satraplatin). Rockville, Md: US Department of Health and Human Services; 2007.